| Owner | Filings | Transaction Date | Type of Owner |
|---|---|---|---|
| Fahey Sandell Jacquelyn | 0001984647 | Jul-10-2023 | officer: Chief Legal Officer |
| SCANGOS GEORGE A | 0001202102 | May-09-2023 | director |
| NEUROCRINE BIOSCIENCES INC | 0000914475 | Feb-23-2023 | 10 percent owner |
| Onyia Jude | 0001894425 | Feb-23-2023 | director |
| Colon Grace | 0001780354 | Jan-01-2023 | director |
| PFREUNDSCHUH PETER P. | 0001585839 | Sep-19-2022 | officer: Chief Financial Officer |
| Carter Todd Alfred | 0001944011 | Sep-19-2022 | officer: Chief Scientific Officer |
| MACKEY CATHERINE J | 0001645330 | Aug-15-2022 | director |
| EcoR1 Capital, LLC | 0001587114 | Apr-21-2022 | 10 percent owner |
| Sandrock Alfred | 0001577061 | Feb-07-2022 | director |
| Swartz Robin | 0001909636 | Feb-07-2022 | officer: Chief Operating Officer |
| Burek Julie | 0001894915 | Nov-26-2021 | officer: Vice President, Finance |
| Vitale Nancy | 0001823262 | Sep-15-2020 | director |
| Khwaja Omar | 0001776393 | May-20-2019 | officer: See Remarks |
| Hesslein Robert W. | 0001585018 | Apr-01-2019 | officer: Senior VP & General Counsel |
| Turenne Andre | 0001747102 | Jul-16-2018 | director, officer: President & CEO |
| Dorval Allison | 0001625110 | Jun-08-2018 | officer: Vice President, Finance |
| Ottmer Matthew P. | 0001659870 | Sep-14-2017 | officer: Chief Operating Officer |
| Sah Dinah Ph.D. | 0001711043 | Jun-29-2017 | officer: Chief Scientific Officer |
| Ravina Bernard | 0001711276 | Jun-29-2017 | officer: Chief Medical Officer |
| DIXON WENDY L | 0001202283 | Jan-01-2017 | director |
| PIERCE GLENN | 0001256964 | Jan-01-2017 | director |
| Henderson Jane | 0001422304 | Jan-01-2017 | officer: Sr. V.P. & CFO |
| LEVIN MARK J | 0001180428 | Dec-19-2016 | director, 10 percent owner |
| TEPPER ROBERT I | 0001192595 | Dec-19-2016 | 10 percent owner |
| STARR KEVIN P | 0001192603 | Dec-19-2016 | 10 percent owner |
| Third Rock Ventures III, L.P. | 0001569705 | Dec-19-2016 | 10 percent owner |
| TRV GP III, LLC | 0001637299 | Dec-19-2016 | 10 percent owner |
| Third Rock Ventures GP III, L.P. | 0001637300 | Dec-19-2016 | 10 percent owner |
| Sanofi | 0001121404 | Nov-10-2015 | 10 percent owner |
| PAUL STEVEN M | 0001237564 | Nov-10-2015 | director, officer: President and CEO |
| GERAGHTY JAMES A | 0001239746 | Nov-10-2015 | director |
| KARSEN PERRY A | 0001260573 | Nov-10-2015 | director |
| Higgins Michael J | 0001478521 | Nov-10-2015 | director |
| Hadley Harbor Master Investors (Cayman) L.P. | 0001641080 | Nov-10-2015 | 10 percent owner |
| Goater Jeff | 0001656435 | Nov-10-2015 | officer: SVP Finance, Bus. Development |
| Hyman Steven | 0001656506 | Nov-10-2015 | director |
Coming soon!
Coming soon!
Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Voyager Therapeutics, Inc.
| Filings | Format | Description | Filed/Effective | File/Film Number |
|---|---|---|---|---|
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072934 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072927 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072926 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072924 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072923 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072922 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072921 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072919 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0001104659-26-072917 ( Act) Size: 0 KB |
Jun-11-2026 | |
| 8-K | Document | Current report filing Acc-no: 0001104659-26-072324 (34 Act) Size: KB |
Jun-10-2026 | 261079661 |
| 8-K | Document | Current report filing Acc-no: 0001104659-26-068591 (34 Act) Size: KB |
Jun-01-2026 | 261047261 |
| 3 | Document | Initial statement of beneficial ownership of securities Acc-no: 0001104659-26-063176 ( Act) Size: 0 KB |
May-18-2026 | |
| 144 | Document | Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-26-003666 (33 Act) Size: 0 KB |
May-15-2026 | 26987249 |
| SCHEDULE 13G/A | Document | Acc-no: 0000935836-26-000263 (34 Act) Size: KB | May-15-2026 | 26985715 |
| SCHEDULE 13G/A | Document | Acc-no: 0001172661-26-002122 (34 Act) Size: KB | May-15-2026 | 26983998 |
| 144 | Document | Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-26-003638 (33 Act) Size: 0 KB |
May-15-2026 | 26983733 |
| 8-K | Document | Current report filing Acc-no: 0001104659-26-057115 (34 Act) Size: KB |
May-07-2026 | 26953182 |
| 10-Q | Document | Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001104659-26-057097 (34 Act) Size: KB |
May-07-2026 | 26953032 |
| ARS | Document | Annual report to security holders Acc-no: 0001104659-26-050335 (34 Act) Size: KB |
Apr-28-2026 | 26907716 |
| DEFA14A | Document | Additional definitive proxy solicitation materials Acc-no: 0001104659-26-050311 (34 Act) Size: KB |
Apr-28-2026 | 26907527 |
Recent 20 filings. View all Voyager Therapeutics, Inc. filings
Thanks I look forward to using the product to improve my skin tone
Very good communication and delivery made within the timeframe I was advised of
Huge help thank you for your help .. y'all make it so much easier
Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.
© 2022 CompaniesBIO.Com. All rights reserved. Operated by